Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Rhea-AI Summary

Syndax Pharmaceuticals (NASDAQ: SNDX), a commercial-stage biopharmaceutical company focused on cancer therapies, has granted inducement awards to 14 new employees. The awards consist of options to purchase up to 228,400 shares of common stock under the Company's 2023 Inducement Plan.

The stock options feature a four-year vesting schedule, with 25% vesting after one year and the remaining shares vesting monthly at a rate of 1/48th over the subsequent 36 months, contingent on continued employment with Syndax.

NEW YORK, July 02, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on July 1, 2025 the Company granted inducement awards to purchase up to 228,400 shares of common stock to 14 new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc. 
sklahre@syndax.com
Tel 781.684.9827

FAQ

What type of inducement awards did Syndax Pharmaceuticals (SNDX) grant in July 2025?

Syndax granted stock options to purchase up to 228,400 shares of common stock under their 2023 Inducement Plan.

How many employees received Syndax (SNDX) inducement awards in July 2025?

14 new employees received inducement awards from Syndax Pharmaceuticals.

What is the vesting schedule for Syndax's (SNDX) July 2025 inducement awards?

The stock options vest over 4 years, with 25% vesting after one year and 1/48th vesting monthly over the following 36 months, subject to continued employment.

What is the purpose of Syndax Pharmaceuticals' (SNDX) inducement awards?

The inducement awards are granted to new employees as part of their compensation package under the Company's 2023 Inducement Plan.